Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.79
- Piotroski Score 4.00
- Grade Buy
- Symbol (EXAS)
- Company Exact Sciences Corporation
- Price $65.96
- Changes Percentage (-2.91%)
- Change -$1.98
- Day Low $65.86
- Day High $68.00
- Year High $79.62
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/29/2024
- Fiscal Year End N/A
- Average Stock Price Target $80.00
- High Stock Price Target $168.00
- Low Stock Price Target $60.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.31
- Trailing P/E Ratio -32.77
- Forward P/E Ratio -32.77
- P/E Growth -32.77
- Net Income $-204,149,000
Income Statement
Quarterly
Annual
Latest News of EXAS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
I'm a Californian who moved to Texas for a shot at the American dream. I moved back after 2 ½ years, but I miss Texas.
Kimberly Wilkerson, a self-published author and entrepreneur, shares her journey of moving from California to Texas for a fresh start. Despite challenges, she found peace and growth in Texas but later...
By Business Insider | 6 hours ago -
A federal judge in Texas will hear arguments over Boeing's plea deal in a 737 Max case
A federal judge in Fort Worth, Texas has ordered a hearing on Boeing's guilty plea to conspiracy related to the 737 Max crashes. Families of crash victims want Boeing to face trial for tougher punishm...
By Yahoo! Finance | 18 hours ago -
Texas AG sues Austin over out-of-state abortion travel
The Texas Attorney General is suing Austin for using $400,000 in taxpayer funds to help residents access out-of-state abortions. Ken Paxton claims the grant violates the state constitution, seeking to...
By The Hill | 22 hours ago
